Cost effectiveness of the type II Boston keratoprosthesis

7Citations
Citations of this article
33Readers
Mendeley users who have this article in their library.

Abstract

Purpose Despite demonstrated cost effectiveness, not all corneal disorders are amenable to type I Boston keratoprosthesis (KPro) implantation. This includes patients with autoimmune diseases, such as Stevens-Johnson syndrome/toxic epidermal necrolysis. Type II KPro is implanted through the eyelids in severe dry eye and cicatricial diseases, and its cost effectiveness was sought.Patients and methodsIn a retrospective chart review, 29 patients who underwent type II KPro surgery at the Massachusetts Eye and Ear Infirmary between the years 2000 and 2009 were identified. A total of 11 patients had 5-year follow-up data. Average cost effectiveness was determined by cost-utility analysis, comparing type II KPro surgery with no further intervention. ResultsUsing the current parameters, the cost utility of KPro from third-party insurer (Medicare) perspective was 63 196 /quality-adjusted life year.ConclusionEfforts to refer those less likely to benefit from traditional corneal transplantation or type I KPro, for type II KPro surgery, may decrease both patient and societal costs. © 2011 Macmillan Publishers Limited All rights reserved.

Cite

CITATION STYLE

APA

Ament, J. D., Stryjewski, T. P., Pujari, S., Siddique, S., Papaliodis, G. N., Chodosh, J., & Dohlman, C. H. (2011). Cost effectiveness of the type II Boston keratoprosthesis. Eye, 25(3), 342–349. https://doi.org/10.1038/eye.2010.197

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free